Algernon Pharmaceuticals Inc.

CSE: AGN, OTCQB: AGNPF, FFT: AGW

Company Logo

Company Overview

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

-$0.68

Diluted EPS (ttm)

Management Team

Mr. Gary D. Kain
Exec. Chairman

Mr. Peter J. Federico
Pres, CEO & Director

Ms. Bernice E. Bell
Exec. VP & CFO

Mr. Christopher J. Kuehl
Exec. VP & Chief Investment Officer

Mr. Kenneth L. Pollack
Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec.

Mr. Aaron J. Pas
Sr. VP

Mr. Christopher Erhorn
Sr. VP & CTO

Ms. Katie R. Wisecarver
VP of Investor Relations

Mr. Sean Reid J.D.
Exec. VP of Strategy & Corp. Devel.

Mr. Jason Campbell
Head of Asset & Liability Management and Sr. VP

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
()

Insider Ownership
3%